A Bellete

Business Leader, Business Builder, Biotech and Med Device Chief Executive, Technology Geek - Views and Tweets are mine and do not represent my company -

[CG Oncology, Inc. @cgoncology]

Today, CG Oncology announced that Arthur Kuan, @KuanArthur , Chairman & Chief Executive Officer, and Ambaw Bellete, @abellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California.

To learn more, please read our release: https://t.co/hWuQ7PygLu

[CG Oncology, Inc. @cgoncology]

The team at CG Oncology is looking forward to returning to this year’s @UroOnc #SUO2025 early next month.

We are proud to have two late-breaking abstracts selected for the conference: topline results from Cohort P of our BOND-003 trial and first results from Cohort A of our CORE-008 trial, both evaluating our lead candidate cretostimogene grenadenorepvec in non-muscle invasive bladder cancer patients.

See our press release here for more information on our late-breakers and our posters at SUO: https://t.co/2thvQ5L6Gp

See you in Phoenix, Dec. 2-5!

#SUO #Urology #BladderCancer #Oncology #CGOncology

[CG Oncology, Inc. @cgoncology]

Last week our team was honored to participate in the annual BCAN Bladder Cancer Think Tank Meeting in Washington D.C. Thank you to #BCAN for convening such an important and impactful forum.

[CG Oncology, Inc. @cgoncology]

In updated Phase 3 BOND-003 data shared at #SUO2024, cretostimogene grenadenorepvec showed sustained, durable complete responses in high-risk BCG-unresponsive #NMIBC. See how CG Oncology is advancing innovation in the fight against #bladdercancer.

[UroToday.com @urotoday]

Breaking Paradigms: #Cretostimogene monotherapy #BOND-003 demonstrates significant durability & tolerability with no major AEs. @FDA grants Fast Track & Breakthrough Therapy designation. @MarkTysonMD discusses on UroToday > https://t.co/yZi3tr3acl #BladderCancer @cgoncology

[Targeted Oncology @TargetedOnc]

WATCH: Background, Methods, and Design of BOND-003 in #NMIBC With @MarkTysonMD | #AUA2024

https://t.co/jBNF9Earhx

[OncLive.com @OncLive]

Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS. #AUA2024 #NMIBC
https://t.co/PiRZFvVd3z

[CG Oncology, Inc. @cgoncology]

We're thrilled to present our latest data today! Join us to hear from @SvatekRob, MD & @MarkTysonMD as they present on their respective ongoing trials: PIVOT-006 at 10:24 am and BOND-003 at 10:56 am CDT in the Learning Lab. Come join us!

👉Full agenda: https://t.co/cOADzltuj9

[CG Oncology, Inc. @cgoncology]

It was a full house at the #AUA2024 "Clinical Trials in Progress, Bladder Cancer" session, featuring presentations by @SvatekRob on the PIVOT-006 study & @MarkTysonMD on the BOND-003- Cohort P. Learn more and discover our latest advances in #bladdercancer at booth #100! 🤝

[The Johns Hopkins Brady Urological Institute @brady_urology]

#AUA24 join @akfsurgeon tomorrow AM for Optimizing Care for Women with #BladderCancer, a course offering up-to-date, evidence-based guidance on surgical mgmt of bladder cancer in women while preserving sexual function.

🗓️Sat, May 4
⏰10-noon (CT)
📍212

https://t.co/o8DwvrqxmZ

[A Bellete @abellete]

Excited to share our advances in #bladdercancer research at @UroOnc's #SUO2023! BOND-003's Phase 3 results presented by @MarkTysonMD of @MayoClinic will cover our innovative #immunotherapy approaches targeting #BCG-unresponsive #NMIBC

📰 https://t.co/j4edZ5NsBg (Abstract #3396)

[A Bellete @abellete]

@pre_rad @elemental Really powerful story...thank you for sharing. The experience you had is shared by many including me.

[A Bellete @abellete]

We want to thank all the patients that participated in the trial and investigators of our Phase 3 trial!@BladderCancerUS @UroOnc

[FerGene @FerGeneBio]

We’re excited to share @TheLancetOncol
has published data from the Phase 3
clinical trial of nadofaragene firadenovec.
Learn more: https://t.co/WA2tk985xl , https://t.co/4HT6ByhvY1 @BladderCancerUS @UroOnc #SUOCTC

[A Bellete @abellete]

Congratulations Rob well deserved!

[UT Health SA Uro @UTHSAUro]

We are delighted to announce the appointment of Robert Svatek, MD, MSCI as Chair, Department of Urology, effective November 30, 2020. Congratulations! @UTHealthSA @UTHResearch

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Importance of repeated stimulation of immune system with maintenance BCG has been known; forgotten; restudied; known again; forgotten; restudied again ... enough times that if someone says to you “I don’t believe in maintenance BCG” just show them the door out #GU20 #GU2020

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

In Depth Assessment of Emerging Therapies for BCG Unresponsive NMIBC
@EurUrolOncol @UroToday @UroCancerMD @WesKassouf @ArjunBalarMD @BrantInman @EUplatinum @BladderCancerUS @MDAndersonNews #BladderCancer
https://t.co/JoDfqjyQ5y

[Piyush K. Agarwal, MD @Agarwal_CaB]

Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing | Global Health | JAMA | JAMA Network - they only have 50 cases! https://t.co/UwD6RVApis

[Sridhar Vembu @svembu]

Really delightful use of machine vision.

[A Bellete @abellete]

10 resolutions for successful leaders to have in the new year https://t.co/WJGNL2tApe via @businessinsider

[A Bellete @abellete]

An extraordinary story of a patient’s will to solve his disease! https://t.co/q7m2hVVNyp